PDF(Pubmed)
Abstract：
UNASSIGNED: Antipsychotic medications can impair vision in patients with schizophrenia. However, little is known regarding the pharmacodynamics of antipsychotics in the primary visual cortex. We aimed to study the pharmacodynamics of antipsychotics in the visual cortex in a murine model.
UNASSIGNED: We used an adapted 2-photon imaging technique to observe changes in calcium dynamics induced by 4 antipsychotics (olanzapine, risperidone, aripiprazole, and amisulpride) in the primary visual cortex of healthy and schizophrenic C57BL/6 mice. Visual function was further assessed by using a novel object recognition test.
UNASSIGNED: All 4 antipsychotics decreased calcium activity in the primary visual cortex and reduced visual recognition test scores in healthy and schizophrenic mice. The most potent drug was olanzapine, followed by risperidone, aripiprazole, and amisulpride. All drugs showed significant differences between groups.
UNASSIGNED: Our pilot study demonstrated that antipsychotics impair visual cortical function. This finding underscores the importance of monitoring for visual adverse events in patients receiving antipsychotic medications to treat schizophrenia.
UNASSIGNED: We used an adapted 2-photon imaging technique to observe changes in calcium dynamics induced by 4 antipsychotics (olanzapine, risperidone, aripiprazole, and amisulpride) in the primary visual cortex of healthy and schizophrenic C57BL/6 mice. Visual function was further assessed by using a novel object recognition test.
UNASSIGNED: All 4 antipsychotics decreased calcium activity in the primary visual cortex and reduced visual recognition test scores in healthy and schizophrenic mice. The most potent drug was olanzapine, followed by risperidone, aripiprazole, and amisulpride. All drugs showed significant differences between groups.
UNASSIGNED: Our pilot study demonstrated that antipsychotics impair visual cortical function. This finding underscores the importance of monitoring for visual adverse events in patients receiving antipsychotic medications to treat schizophrenia.
摘要：
■抗精神病药物会损害精神分裂症患者的视力。然而,关于抗精神病药物在初级视觉皮层中的药效学知之甚少。我们旨在研究抗精神病药物在小鼠模型视觉皮层中的药效学。
■我们使用了适应性的2光子成像技术来观察4种抗精神病药（奥氮平，利培酮,阿立哌唑,和氨磺必利）在健康和精神分裂症C57BL/6小鼠的初级视觉皮层中。通过使用新颖的物体识别测试来进一步评估视觉功能。
■所有4种抗精神病药均降低了健康和精神分裂症小鼠的初级视觉皮层中的钙活性，并降低了视觉识别测试得分。最有效的药物是奥氮平,其次是利培酮,阿立哌唑,还有氨磺必利.所有药物在组间均表现出显著差异。
■我们的初步研究表明，抗精神病药损害视皮层功能。这一发现强调了监测接受抗精神病药物治疗精神分裂症患者视觉不良事件的重要性。
■我们使用了适应性的2光子成像技术来观察4种抗精神病药（奥氮平，利培酮,阿立哌唑,和氨磺必利）在健康和精神分裂症C57BL/6小鼠的初级视觉皮层中。通过使用新颖的物体识别测试来进一步评估视觉功能。
■所有4种抗精神病药均降低了健康和精神分裂症小鼠的初级视觉皮层中的钙活性，并降低了视觉识别测试得分。最有效的药物是奥氮平,其次是利培酮,阿立哌唑,还有氨磺必利.所有药物在组间均表现出显著差异。
■我们的初步研究表明，抗精神病药损害视皮层功能。这一发现强调了监测接受抗精神病药物治疗精神分裂症患者视觉不良事件的重要性。
